Abstract
The level of evidence for the management of prostate cancer progressing after triplet therapy is currently low. Molecular profiling of patients and enrolment in clinical trials are strongly recommended.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have